| Mercier et al. [30]Montréal, Canada. | 32 postmenopausal women (≥ 55 years, mean age of 68.0 ± 6.6) with genitourinary syndrome of menopause and stress or mixed urinary incontinence.Design: A single-arm feasibility study embedded in a randomized controlled trial | Primary outcome:Sexual function (ICIQ-FLUTSsex, sexual function item of the ASQ and sexual matters subscale of the ICIQ-VS)Secondary outcomes:Condition-specific QoL (total score and 4 items of the ASQ, QoL subscale of the ICIQ-VS)
| Exercise intervention (12 weeks):-Sessions of 1 hour: An intensive PFM physiotherapy treatment with a 15-minute educational part and a 45-minute exercise part (strength, resistance, PFM coordination, and functional PFMT exercises) -5 days per week: four home-based PFM exercises (9-30 repetitions). | Measurements:-At baseline.-At 12 weeks.Dropout: 3 (9.06%)Adverse effects:No adverse effects were reported. | Within-group comparisons:-Pre1-post:There were improvements in dyspareunia impact on sexual function (ASQ), sexual matters subscale of the ICIQ-VS, and ICIQ-FLUTSsex score (p = 0.004, p = 0.001 and p = 0.014 respectively). Benefits were also observed in QoL subscale of the ICIQ-VS (p < 0.001) and in ASQ, more precisely in the total score (p < 0.001) as well as in the items vaginal dryness (p = 0.001) and vulvo-vaginal irritation (p = 0.004) impact on activities of daily living.-Pre2-post:Improvements were described in ASQ items dyspareunia impact on sexual function (p = 0.004), and in the ASQ total score (p < 0.001), as well as in the ASQ items vaginal dryness (p = 0.041) and vulvo-vaginal irritation (p = 0.001) impact on activities of daily living. |
| Schvartzman et al. [25]Porto Alegre, Brazil | 42 peri- and postmenopausal women aged 40-60 years with dyspareunia (at least 6 months).EXP 1 (n = 21, 51.9 ± 5.3 years)EXP 2 (n = 21, 50.6 ± 4.7 years)Design: Randomized controlled trial | Primary outcome:Sexual function (FSFI). Quality of sexual life related to menopausal symptoms (Cervantes Scale sexuality subscale). Secondary outcome: Impact of menopausal symptoms on QoL (Cervantes Scale). | -EXP1: 5 sessions (1 hour) of thermotherapy for relaxation of pelvic floor muscles, myofascial release of PMF trigger points, and PFMT. -EXP2: 5 sessions (1 hour), heat applied to the lower back with myofascial release of abdominal diaphragm, piriformis, and iliopsoas muscles. No PFMT. | Measurements: -At baseline-After the intervention.Dropout: EXP1: 1 (4.76%)EXP2: 3 (14.86%)Adverse effects:Not mentioned. | Within-group comparisons:EXP1: improvements in all FSFI subscales and total score, as well as in menopause and health and sexuality Cervantes subscales and total score.Between-group comparisons:EXP1: improvements in lubrication and pain FSFI subscales and total score, as well as in menopause and health Cervantes subscale. |
| Nazarpour et al. [20]Chalous and Noshahr, Iran. | 104 postmenopausal women (40-60 years):-EXP (n = 52, 53.3 ± 2.67 years).-CON (n = 52, 52.84 ± 3.99 years).Design: Randomized controlled trial. | Primary outcome:Sexual function (FSFI). Improvement in sexual function (binary question). | -EXP: 12 weeks. PFM exercises (contraction of the muscles for 10s, relaxation for 10 s and repetition for 10 times in 3-4 sessions a day) with written material, images and videos.-CON: received general information as to the physiological and psychological symptoms of menopause.Both groups also received sex educational booklets. | Measurements:-At baseline.-At 12 weeks.Dropout:EXP: 5 (9.62%)CON: 2 (3.84%)Adverse effects:Not mentioned. | Between-group comparisons:Compared to CON, EXP showed significantly higher scores only in FSFI domains arousal (p = 0.034), orgasm (p = 0.028) and satisfaction (p = 0.011), and reported more improvement in their sexual function (binary question, p = 0.004). |
| Nazarpour et al. [21]Chalous and Noshahr. Northerm Iran. | 156 postmenopausal women (40-60 years):-EXP1 (n = 52, 51.5 ± 3.4 years).-EXP2 (n = 52, 53.1 ± 2.7 years).-CON (n = 52, 52.9 ± 4.0 years).Design: Randomized controlled trial. | Primary outcome:Sexual function (FSFI). Improvement in sexual function (binary question). | -EXP1: 12 weeks. Formal sex education program focused on various aspects of sexual function during menopause.EXP2: 12 weeks. PFMT (Kegel exercises using oral descriptions, written material, images, and videos, and checklists for daily exercise).-CON: participants received general educational material about menopause. | Measurements:-At baseline.-At 12 weeks.Dropout:EXP1: 4 (7.69%) EXP2: 5(9.62%)CON: 2(3.85%)Adverse effects:Not mentioned. | Between-group comparisons: Compared to CON, both EXP1 and EXP2 showed significantly higher scores in arousal FSFI domain (p < 0.05), and improvement in sexual function (binary question, p < 0.001), while only EXP2 showed significantly better scores in orgasm (p = 0.015). |
| Panman et al. [26]Groningen, the Netherlands. | 162 women aged ≥ 55 years with pelvic organ prolapsed:-EXP1 (n = 80 and 4 did not received treatment as randomized. 65.6 ± 6.4 years.)-EXP2 (n = 82 and 35 did not received treatment as randomized. 64.9 ± 7.4 years.)Design: Randomized controlled trial. | Primary outcome:Sexual function (PISQ-12).Secondary outcome:Condition-specific QoL (PFIQ-7)Generic QoL (physical and mental components of the SF-12). | -EXP1: 3-5 times per week, 2-3 times each day. PFMT with specific exercises adapted to the needs of each participant.-EXP2: Silicone pessary treatment. | Measurements:-At baseline.-At 24 monthsDropout: EXP1: 9 (11.25%) and 10 (12.50%) discontinued training protocol.EXP2: 8 (9.76%) and 12 (14.63%) discontinued pessary treatmentAdverse effects:EXP1: increased vaginal discharge (n = 14) and urinary incontinence (n = 5), irritation or erosions of the vaginal walls on physical examination (n = 10). EXP2: No adverse effects were reported. | Between-group comparisons:1. Intention to treat analysis (all participants): No significant differences were observed.2. Per-protocol analysis (participants who completed the intervention to which they were allocated): EXP2 showed significant improvements in sexual function (p = 0.028), and EXP1 in the physical component of the SF-12 (p = 0.004). No other significant differences were reported. |
| Ngowsiri et al. [22]Bangkok, Thailand. | 54 postmenopausal women (45-59 years):-EXP (n = 27, 52.9 ± 4.3 years).-CON (n = 27, 50.7 ± 3.6 years).Design: Randomized controlled trial. | Primary outcome:Quality of sexual life related to menopausal symptoms (MENQOL sexual domain).Secondary outcomes:Impact of menopausal symptoms on QoL (MENQOL vasomotor, physical and psychosocial domains). | -EXP: 13 weeks. Week 1: One session (120 minutes) which consisted of Rusie Dutton exercise explanation and training in deep breathing techniques. Weeks 2-13: Rusie Dutton practice sessions (90 minutes) performed 3 times in the second week, twice in class and once at home in the third week, once a week in class and at least 2 days/week.-CON: No intervention. Both groups received a menopausal health promotion manual. | Measurements:-At baseline.-At 13 weeks.Dropout:EXP: 3 (12.5%)CON: 1 (3.85%)Adverse effects:Not mentioned. | Within-group comparisons:EXP improvements in MENQOL-sexual domain (p = 0.004), MENQOL-vasomotor domain (p = 0.005), MENQOL-psychosocial domain (p = 0.010) and MENQOL-physical domain (p = 0.002).Between-group comparisons:Compared to CON, EXP showed significant improvements in MENQOL-sexual domain (p = 0.003), as well as in MENQOL-vasomotor domain (p = 0.040), MENQOL-psychosocial domain (p = 0.000) and MENQOL-physical domain (p = 0.000). |
| Reed et al. [24]Indianapolis, Oakland, and Seattle, USA. | 355 peri and postmenopausal women (40-55 years):-EXP1 (n = 107, 54.3 ± 3.9 years).-EXP2 (n = 106, 55.8 ± 3.6 years).-CON (n = 142, 54.2 ± 3.5 years).Design: Randomized controlled trial. | Primary outcomes:Sexual function (FSFI), Quality of sexual life related to menopausal symptoms (MENQOL sexual domain)Secondary outcomes:Impact of menopausal symptoms on QoL (MENQOL, HFRDIS). | -EXP1: 12 weeks. Once per week. Sessions of 90 minutes. Yoga (breathing exercises, 11-13 poses and guided meditation). Daily home (20 minutes) on days not attending class.-EXP2: 12 weeks. 3 times per week. Sessions of 40-60 minutes. Moderate-intensity aerobic exercise. Individual cardiovascular conditioning training sessions at 50-60% of the heart rate reserve (first month) and 60-70% (the remainder of the intervention).-CON: usual physical activity.Before allocation to EXP1, EXP2 and CON, all women received either a placebo containing olive oil or an active omega-3 capsule. | Measurements:-At baseline.-At 12 weeks.Dropout:EXP1: 22 (20.56%)EXP2: 27 (25.47%)CON: 25 (17.61%)Adverse effects:Not mentioned. | Between-group comparisons:Compared to CON: EXP1 showed improvements after intervention in MENQOL sexual domain (p = 0.03) as well as in MENQOL total score (p = 0.02), MENQOL vasomotor domain (p = 0.02), and hot flash-related daily interference assessed with the HFRDIS (p = 0.03).Compared to CON, EXP2 showed improvements after intervention in MENQOL physical domain (p = 0.02).No other significant results were observed. |
| Zhang et al. [23]Beijing, China. | 157 perimenopausal women (40 to 55 years, KMI ≥ 15):-EXP (n = 78, 47.82 ± 4.58 years).-CON (n = 79, 48.64 ± 5.24 years).Design: Randomized controlled trial. | Primary outcome:Quality of sexual life related to menopausal symptoms (one item of the modified KI).Secondary outcomes:Impact of menopausal symptoms on QoL (Modified KI score). | -EXP: 12 weeks. 3 times per week. Sessions of 30 minutes. The aerobic physical activity was walking with strides of 60-70 cm long, completing 100 m within 60-70 seconds. In addition, this group attended a collective exercise sessions.CON: usual activity | Measurements:-At baseline.- At 4 weeks.-At 8 weeks.-At 12 weeks.Dropout:EXP: 24 (30.77%)CON: 22 (27.85%)Adverse effects:Not mentioned. | Within-group comparisons:-EXP showed improvements in sexual life (one item of the modified KMI, (p < 0.005) as well as in total modified KMI total score (p < 0.001) and all KMI items. Between-group comparisons: -After intervention, and compared to CON, EXP showed improvements in sexual life (p < 0.05) and modified KMI total score (p < 0.001), as well as other modified KMI items: paresthesia (p < 0.05), insomnia (p < 0.05), irritability (p < 0.001), fatigue (p < 0.05), bone/joint/muscle pain (p < 0.001), headache (p < 0.05), formication (p < 0.05). |
| Duijts et al. [27]Amsterdam and Rotterdam, the Netherlands. | 422 women with primary breast cancer (stages, T1-4, N0-1, and M0), with treatment-induced menopause (48.2 ± 5.6 years).-EXP1 (n = 109, 48.2 ± 5.7 years)-EXP2 (n = 104, 47.7± 5.6 years) -EXP3 (n = 106, 49.0 ± 4.9 years)-CON (n = 103, 47.8 ± 6.0 years)Design: Randomized controlled trial. | Primary outcome:Sexual function (SAQ).Secondary outcomes:Quality of sexual life related to menopausal symptoms (HF/NS problems assessed with HFRS), depressive and anxiety symptoms (HADS), generic QoL (SF-36). | -EXP1: 12 weeks. 6 times per week. Sessions of 90 minutes. Cognitive-behavioural treatment with relaxation exercises. A booster session was held 6weeks after completion of the program.-EXP2: 12 weeks. 2.5-3 hours per week. Individually tailored, self-directed exercise program (swimming, running, cycling, etc.). Target heart rate: 60% to 80% Karvonen. Last week: final session in which they received advice on the best way to maintain the desired level of physical activity-EXP3: underwent EXP1 and EXP2 simultaneously.-CON: No intervention. | Measurements:-At baseline.-At 12 weeks.-At 6 months.Dropout:1. All patients:-At 12 weeks:EXP1: 23 (21.10%)EXP2: 17 (16.35%)EXP3: 16 (15.09%)CON: 14 (13.59%)-At 6 months:EXP1: 21 (19.27%)EXP2: 25 (24.04%)EXP3:17 (16.04%)CON: 19 (18.45%)2. Patients who did not meet criteria for minimal compliance with the intervention(s). EXP1: 58%EXP2: 64%EXP3: 70%Adverse effects:Not mentioned. | Between-group comparisons (compared to CON):1. Intention to treat analysis (all participants):-At 12 weeks, EXP1 (p = 0.001), EXP2 (p < 0.001) and EXP3 (p = 0.001) showed improvements at SF-36 physical functioning domain.-At 6 months, EXP1 (p = 0.042) and EXP3 (p = 0.002) exhibited significant improvements in sexual function (SAQ habit subscale), while only EXP2 (p = 0.002) showed improvements regarding SF-36 physical functioning subscale2. Per-protocol analysis (participants who met criteria for compliance). Only EXP1 and EXP 3 showed improvements:-At 12 weeks, significant benefits were described for EXP1 at SAQ- pleasure subscale (p = 0.002), HF/NS problem (p < 0.001), and SF-36 subscales of physical functioning (p = 0.003), vitality (p = 0.002), mental health (p = 0.042) and mental component (p = 0.015). For EXP 3, improvements were observed in HF/NS problem (p < 0.001), and SF-36 subscales of physical functioning (p = 0.003), vitality (p = 0.009), role emotional (p = 0.001), mental health (p = 0.002) and mental component (p = 0.002).-At 6 months, improvements were found for EXP1only at SAQ- pleasure subscale (p = 0.022) and HF/NS problem (p < 0.001), while EXP3 showed benefits in HF/NS problem (p < 0.001), and SF-36 subscales of role emotional (p = 0.033), mental health (p = 0.002) and mental component (p = 0.019). |
| Lara et al. [28]São Paulo, Brasil. | 45 sedentary postmenopausal women (46–58 years, mean age of 52.1 ± 3.5 years, not > 5 years of menopause).Design: Prospective, longitudinal exploratory study. | Primary outcome:Sexual function (SQ-F).Secondary outcomes:Anxiety and depression (HADS). | Exercise intervention: 12 weeks. 2 times per week. Sessions of 60 minutes. Physical exercise program which consists of 4 sets of 10 repetitions of maximal PFMT. The program also included warm-up exercises (10 minutes), stretching (10 minutes), muscle strengthening exercises (35 minutes), and relaxation (5 minutes).In addition, they had to do exercises at home three times a week. | Measurements:-At baseline.-At 12 weeks.Dropout:13 (28.88%)Adverse effects:Not mentioned. | Within-group comparisons:After exercise intervention, there were no significant results regarding sexual function. The number of women with anxiety was significantly less (p < 0.01), but any other results were found. |
| Mastrangelo et al. [29]New Jersey, USA. | 19 peri- and postmenopausal women aged 46-63 years old (mean age 54.8 years).Design: Pre- to post-test of convenience. | Primary outcomes:Quality of sexual life related to menopausal symptoms (MENQOL-sexual domains).Secondary outcomes:Impact of menopausal symptoms on QoL (MENQOL vasomotor, physical and psychosocial domains). | Exercise intervention: 8 weeks. 2 times per week. Sessions of 50 minutes. The training consisted of a 5-minute cardiovascular warm-up (on a stationary bicycle), a 40-minute circuit training program (aerobic and resistance exercises, with 10 hydraulic machines and 3 types of aerobic exercise), and finished with a 5-minute stretch/cool down. | Measurements:-At baseline.-At 8 weeks.Dropout: 7(36.84%).Adverse effects:Not mentioned. | Within-group comparisons:After exercise intervention, there were no significant results regarding sexual function or any other domains of the MENQOL, except for the physical domain (p = 0.008). |